• Clinical Trials - Hepatocellular Cancer

    Study Objective Contact
    A Phase 3, Randomized, Double-Blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib [LCID Study Number: 2013-064] There are no approved therapies for second line treatment of HCC. The purpose of this study is to see if Cabozantinib (XL184) will help patients whose disease worsened after prior treatment with Sorafenib. Patients will receive either study drug or placebo. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    A Prospective, Multicenter Comparison Of Multiphase Contrast -Enhanced CT And Multiphase Contrast-Enhanced MRI For Diagnosis Of Hepatocellular Carcinoma And Liver Transplant Allocation [LCID Study Number: 2010-064] A Prospective, Multicenter Comparison Of Multiphase Contrast -Enhanced CT And Multiphase Contrast-Enhanced MRI For Diagnosis Of Hepatocellular Carcinoma And Liver Transplant Allocation Principal Investigator(s):
    Sebastian Flacke, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Nanette Matrullo.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.